Displaying drugs 15051 - 15075 of 15133 in total
5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole
5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. 5-(5-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)pentyl)-3-(hydroxyethyl oxymethyleneoxymethyl) isoxazole targets the protein genome polyprotein.
Experimental
Ponazuril
Ponazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.
Vet approved
Henagliflozin
Henagliflozin has been used in trials studying the treatment of Type 2 Diabetes.
Investigational
Chlorproguanil
Chlorproguanil has been used in trials studying the treatment of MALARIA. It is a dichloro-derivative of chloroguanide.
Investigational
Clofoctol
Experimental
Tolpropamine
Experimental
Suloctidil
Experimental
Eprozinol
Experimental
Etybenzatropine
Experimental
Tiocarlide
Experimental
Quifenadine
Experimental
Penfluridol
Experimental
Nifurpirinol
Experimental
Vet approved
Urapidil
Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.
Investigational
ACA 125
An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.
This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host...
Investigational
Matched Description: … To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow …
Cannabinol
Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Experimental
Investigational
Matched Categories: … Cannabinoids and similars …
BIA
Experimental
XL019
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
Displaying drugs 15051 - 15075 of 15133 in total